Background: retinoblastoma (RB) is a rare inherited eye disease. Leukocoria is the first presenting sign of this disease. Early diagnosis is important to gain better life outcomes. We aim to assess Kafr Elsheikh university medical students' knowledge about retinoblastoma. Methodology: A cross-sectional study was performed using a web-based questionnaire to collect data. We analyzed the data using the SPSS program. Results: we survived 235 medical students and graduates at Kafr Elsheikh university. Most participants (n=131, 55.7%) had sufficient knowledge about retinoblastoma, while 78 (33.2%) had poor knowledge. Only 26 (11.1%) had a proficient level. Almost all participants (99.6%) detected that the abnormal eye was due to disease. Nearly two-thirds (63%) thought that it was a life-threatening leukocoria. While (96.6%) knew that an ophthalmologist referral was the right thing to do. We found no significant differences between academic grades and test results (H= 1.093, P=.779). As well, no correlation was found between academic grades and results (r=.033, p=.086). Conclusion: Retinoblastoma is a fatal disease that needs attention in developing countries. Early detection of RB is the key to successful management with a higher survival rate. All healthcare providers, particularly those who have direct contact with children, should receive comprehensive education to improve their clinical screening skills.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.